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Abstract
Objective As there are pharmacological differences
between males and females, and glucocorticoid (GC)
treatment is associated with increased cardiovascular
mortality rate in rheumatoid arthritis (RA) patients, it is
important to study serum polar lipid profiles of male and
female patients in response to GC therapy. Gender differ-
ences may require an adjustment to the treatment strategy
for a selection of patients.
Methods Serum samples from 281 RA patients were
analysed using a targeted lipidomics platform. The differ-
ences in GC use and gender on polar lipid profiles were
cross sectionally examined by multiple linear regressions,
while correcting for confounding factors.
Results Differences in polar lipids between GC users and
non-GC users in females and males were merely restricted
to lysophospholipids (lysophosphatidylcholines and
lysophosphatidylethanolamines). Lysophospholipids in
female patients treated with GCs were significantly higher
than female patients not treated with GCs (p = 6.0 E-6),
whereas no significant difference was observed in male GC
users versus non-users (p = 0.397).
Conclusion The lysophospholipid profiles in response to
GCs were significantly different between male and female
RA patients, which may have implications for the cardio-
vascular risk of GC treatment.
Keywords Gender difference  Lysophospholipid 
Glucocorticoid  Rheumatoid arthritis
Introduction
Rheumatoid arthritis (RA) is an auto-immune disease with
unresolved aetiology which predominantly occurs in
females (Jutley et al. 2015). Glucocorticoids (GCs) have
been prescribed for the treatment of RA for decades, and
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are considered to be effective drugs in reducing inflam-
mation and preventing joint destruction (Hoes et al. 2007).
The role of gender as a crucial factor in drug studies is
becoming increasingly appreciated (Soldin and Mattison
2009). Several studies have investigated the effects of
gender on clinical pharmacology for GCs on healthy vol-
unteers, and showed gender specific differences in GC
pharmacokinetics and pharmacodynamics (Lew et al. 1993;
Magee et al. 2001). However, these differences are bal-
anced by complementary GC clearance and GC sensitivity.
Therefore, these gender differences do not necessitate GC
dose adjustments in clinical practice.
Glucocorticoids are known to undesirably affect triacyl-
glyceride and fatty acidmetabolism (Macfarlane et al. 2008).
It is thus conceivable that GC-induced changes of lipid
profiles in RA patients also show gender dependence, apart
from the gender differences in lipid metabolism seen in the
general population (Wang et al. 2011). Because GC treat-
ment is associated with increased cardiovascular mortality
rate in RA patients (del Rinco´n et al. 2014; McGrath and
Young 2015), it is important to study these gender-based
lipid differences as they may require an adjustment in
treatment strategy for a selection of the patients.
In this study, we measured circulating polar lipids, such
as lysophospholipids and free fatty acids, in the serum of
RA patients using a targeted lipidomics platform, because
polar lipids are crucial intermediates in lipid metabolism.
Lipid profiles between GC users and non-GC users were
examined and analysed for gender differences. Our results
suggested that the lipid profile is more affected by GC
treatment in female RA patients. In particular, the levels of
lysophospholipids were more elevated in female users
compared to non-users. In males, the differences of
lysophospholipid levels in GC users were not significant
compared to non-users.
Methods and materials
Subjects in this study were participants of an observational
study BiOCURA, in which RA patients initiating or
switching from biological therapy were recruited (Cuppen
et al. 2016). Blood samples were collected before initiating
the biological therapy and immediately processed into
serum. Serum samples were stored at -80 C until use for
lipidomic analyses. At the time of sampling, 42.35 % of
patients were receiving GCs, including prednisolone and
prednisone, at varying dosages (all medications are listed in
Supplementary Table S1). The study was approved by the
medical ethics committee of the University Medical Center
Utrecht and the institutional review boards of the partici-
pating centers (see Acknowledgements). Written informed
consent was obtained from each patient.
The operating procedures of the targeted lipidomics
platform are optimised from the previously published
method (Hu et al. 2008). Polar lipids are extracted by
methanol from serum samples, and analysed by liquid
chromatography–mass spectrometry, covering the low
abundance lipid species, including free fatty acids and
lysophospholipids—lysophosphatidylcholines (LPCs) and
lysophosphatidylethanolamines (LPEs). Details of the
procedures are described in the Supplementary Method.
A schematic overview of the statistical analyses is pro-
vided in Supplementary Fig. S1. Initially, the obtained lipid
data set was log-transformed and standardised into Z scores
to produce normalised and auto-scaled data (mean = 0,
SD = 1). Then, the differences in lipids between GC users
andGCnon-users were calculated and tested for significance
by independent t tests for male and female subjects sepa-
rately. In parallel, principal component analysis (PCA) was
performed on all detected lipids to elucidate the correlation
structure of the metabolites. By combining the results of the t
tests, PCA, and prior biological knowledge, a decision was
made on which lipids can be clustered into a new lipid score
to have one overall outcome for subsequent analyses. For
each patient, the score was computed by summing the stan-
dardized values of lipids and dividing this by the number of
included lipids (
PN
i Standardised lipidi/N, with N = num-
ber of lipids clustered). This value represents both the
average of lipids, as well as the patients’ relative deviation
from the mean lipid score in standard deviations (SDs).
Multiple linear regression analysis was then conducted to
study the effect of GC use between males and females on the
lipid score. We entered the following subgroups in the
model—female GC user (n = 77), female GC non-user
(n = 136), male GC user (n = 42), and male GC non-user
(n = 26) together with the clinical parameters (listed in
Supplementary Table S1) as a full model, while setting the
subgroup ‘‘female GC non-user’’ as the reference group (i.e.,
the intercept of the regression model). To arrive at a final
model, backward elimination was applied on the full model
by excluding clinical parameters one by one on p values
(starting from highest to lowest p value). Parameters were
excluded only when the change in the regression coefficients
after exclusion was\10 % for all four subgroups; otherwise,
the clinical parameter was kept in themodel as a confounder.
To explore the difference in lipid score between GC users
and non-users inmales, the reference group in the finalmodel
was switched to ‘‘male GC non-users’’.
Results and discussion
In the patient cohort (n = 281), there were more males
taking GCs than females (61.8 versus 35.8 %, p\ 0.01).
There were no significant differences in disease activity
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of t tests results in lipid
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among the relevant groups (Supplementary Table S1).
However, the number of smokers was especially high in
males (p\ 0.001), positive rheumatoid factor was high
amongst male GC users (p = 0.004), GC users used less
non-steroidal anti-inflammatory drugs (NSAIDs)
(p = 0.010) and more bisphosphonates (to reduce the risk
of GC-induced osteoporosis) (p\ 0.001).
By applying an established lipidomics platform, serum
lipid profiles of the 281 RA patients were analysed, cov-
ering 44 lysophospholipids and 24 free fatty acids
(Supplementary Table S2). T tests between GC users and
non-users were performed (Supplementary Table S3; a
graphical representation is shown in Fig. 1). In females, we
identified 10 LPEs and 22 LPCs which were significantly
higher in GC users than in GC non-users (p\ 0.05),
whereas no differences were found in fatty acids. However,
in male subjects, only one LPE (LPE (20:5), p = 0.029)
and LPC (sn1-LPC (18:2), p = 0.027), which were sig-
nificant in females, were found significantly higher in GC
users, whereas one fatty acid (FA (20:3-x9), p = 0.021)
was significant lower in male GC users among all mea-
sured FAs. These results suggest that the GCs have a more
pronounced impact on female lysophospholipid profile
compared to males.
The parallel PCA analysis on 68 metabolites showed
that the loading scores of all 32 significant lysophospho-
lipids were larger than 0.4 in the first component, thus
highly correlated with each other (Supplementary Fig. S2,
Table S4). A new score representing the lysophospholipid
levels could, therefore, be computed by calculation of the
mean of all significant lysophospholipids. As shown in
Fig. 2, the absolute lysophospholipid scores were signifi-
cantly different between female GC users and non-users
(p\ 0.001), whereas no difference was seen in males
(p = 0.450). In addition, female GC users showed signif-
icantly higher values compared to male GC users
(p = 0.041), whereas no difference was seen between
female and male non-users (p = 0.548).
After backward elimination for potential confounders, a
final model for the lysophospholipid score was established
(Table 1). Subgroups of males and female GC users all had
significant positive coefficients, which suggest that the
lysophospholipid score of these subgroups was signifi-
cantly higher compared to females not using GCs. In
particular, females using GCs had a significant increase in
mean lysophospholipid score of 0.398 (p = 6E-6), com-
pared to females not using GCs. Interestingly, the
difference between male and female non-users was not
significant before correcting for confounders (p = 0.548,
Fig. 2), while it was significant in the final model (coeffi-
cient = 0.310, p = 0.041). The difference between GC
users and non-users in males was non-significant (0.122,
p = 0.397; model with ‘‘male GC non-users’’ as a
reference shown in Supplementary Table S5). Therefore,
after correcting for confounders, the lysophospholipids
score of female RA patients taking GCs was still signifi-
cantly higher than the female patients not taking GCs,
whereas in male RA patients, no difference in lysophos-
pholipid score was seen. This was consistent with the
results of the t tests on individual lipids and the uncorrected
difference in lysophospholipid score.
Patients with RA already have a higher cardiovascular
disease risk and this elevated risk is only partly explained
by the increased prevalence of traditional cardiovascular
risk factors, such as age, gender, dyslipidaemia, hyperten-
sion, smoking, obesity, and diabetes mellitus
(Nurmohamed et al. 2015). In addition, systemic inflam-
mation and genetic factors also play a role (Nurmohamed
et al. 2015). More recently, GC use has been directly
related to an (dose-dependent) increase in cardiovascular
death in RA (del Rinco´n et al. 2014). However, in this
study, no effect on lipid profiles by different dosages was
seen, as the factor low (\7.5 mg) versus moderate-to-high
([7.5 mg) dosage was excluded during confounder selec-
tion. A possible protective effect can be expected from
concomitant use of hydroxychloroquine, which signifi-
cantly lowered lysophospholipid scores in our study
(decrease in mean lysophospholipid score = 0.180, 95 %
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Fig. 2 Lyophospholipid score in male patients without (n = 26) or
with glucocorticoid (GC) treatment (n = 42), and in female patients
without (n = 136) or with GC treatment (n = 77). Horizontal bars
indicate mean values and standard deviation. One-way ANOVA with
Fisher’s LSD was used to compare the means of score among
subgroups
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CI (-0.347 to -0.013), p = 0.035; Table S5). It has also
been reported to improve cholesterol levels, notably, in
those treated with GCs (Hage et al. 2014).
Lysophospholipids, including lysophosphatidylcholine
(LPC) and lysophosphatidylethanolamine (LPE), are an
abundant lipid species, mainly functioning as transporters
for free fatty acids. The difference between LPC and LPE
is based only on the functional head group, respectively,
choline or ethanolamine. The functions of LPEs are
underreported, hampering their biological interpretation.
Studies show that LPCs have properties resembling extra-
cellular growth factors and signalling molecules (Ishii et al.
2004). In vivo, LPCs are generated from phospholipase A1/
A2 catalysed hydrolysis of phosphatidylcholines, the basic
component of membranes (Pruzanski et al. 2007). In
addition, LPCs are released from phosphatidylcholines by
the action of lecithin cholesterol acyltransferase in plasma
(Kougias et al. 2006). Most of the circulating LPC is bound
to albumin, but they are also a major component of
lipoprotein particles, where they are a known constituent of
oxidised low-density lipoproteins (LDL) (Chisolm and
Chai 2000; Marathe et al. 2001), a well-known risk factor
for cardiovascular diseases (Maiolino et al. 2013). The
lysophospholipid-related gender differences are, therefore,
potentially relevant with respect to the risk of cardiovas-
cular events in RA patients, which could eventually guide
the adjustment of treatment strategies for either males or
females.
As patients were included in BiOCURA based on the
necessity of biological treatment and not GC treatment, it
was only possible to use samples of users and non-users,
but not before and after GC initiation. Future studies are
needed to validate our results, preferably before and after
initiation of GC treatment. In addition, the role of lipid
profiles (including triglycerides, diglycerides, and sphin-
gomyelins) in the association between GC use, gender, and
cardiovascular death should be clarified to fully understand
and (specifically) prevent unwanted clinical (side)effects.
Conclusion
After correcting for confounding factors, lysophos-
phatidylcholines and lysophosphatidylethanolamines in
female RA patients with GC treatment were significantly
higher than in female patients not taking GCs, whereas in
male RA patients, these lysophospholipids levels were
similar between GC users and non-users. These results
could contribute to a better understanding and estimation of
safety of GC drugs for male and female RA patients sep-
arately, particularly in relation to cardiovascular events.
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Table 1 Final regression model investigating the association between
gender and glucocorticoid (GC) use on the lysophospholipid score
corrected for confounders. Shown is the difference in mean
lysophospholipid score for subgroups compared to females not using
GCs (as reference group)
Variables Coefficientsa (95 %-CI) p value
Female GC non-user (reference group) -0.161 (-0.729 to 0.408) 0.580
Female GC user 0.398 (0.229 to 0.567) 6.0 E-6
Male GC non-user 0.310 (0.015 to 0.604) 0.041
Male GC user 0.432 (0.164 to 0.700) 1.7 E-3
BMI body mass index, CI confidence interval, CRP C-reactive protein, GC glucocorticoid, RF rheumatoid factor, ACPA anti-citrullinated protein
antibody, ESR erythrocyte sedimentation rate, DAS28 disease activity score based on a 28-joint count, NSAIDs non-steroid anti-inflammatory
drugs
a Coefficients indicate the changes in mean lysophospholipid score, adjusting for: age, BMI, menopausal status, RF positive, log-transformed
CRP, log-transformed ESR, DAS28, and concomitant drugs (methotrexate, hydroxychloroquine, anti-diabetic drug and NSAIDs)
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